Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
News|Articles|July 18, 2023
Alzheimer Disease Pipeline Update: Inside Look at Promising Agents
Author(s)Marco Meglio, Isabella Ciccone, MPH
With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.
Advertisement
Advertisement
There are an estimated 6.3 million individuals with Alzheimer disease (AD) dementia in the United States, and an estimated 50 million individuals with AD dementia globally. These populations are expected to grow to 12.7 million and 150 million in the US and globally, respectively, by 2050. Fortunately, though, in recent years, drug development has expanded significantly, with several dozens of agents currently progressing through the pipeline.
Related to this article
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement